Olacaftor

• CAT Number: I033840
• CAS Number: 1897384-89-2
• Molecular Formula: C29H34FN3O4S
• Molecular Weight: 539.67
• Purity: 98%
• Synonyms: Olacaftor; VX-440; VX 440; VX440
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).
• IUPAC Name: N-(benzenesulfonyl)-6-[3-fluoro-5-(2-methylpropoxy)phenyl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide
• InChI: InChI=1S/C29H34FN3O4S/c1-19(2)18-37-23-14-21(13-22(30)15-23)26-12-11-25(27(31-26)33-17-20(3)16-29(33,4)5)28(34)32-38(35,36)24-9-7-6-8-10-24/h6-15,19-20H,16-18H2,1-5H3,(H,32,34)/t20-/m0/s1
• InChIKey: NHOUNZMCSIHKHJ-FQEVSTJZSA-N
• SMILES: O=C(C1=CC=C(C2=CC(OCC(C)C)=CC(F)=C2)N=C1N3C(C)(C)C[C@H](C)C3)NS(=O)(C4=CC=CC=C4)=O

Olacaftor is a CFTR potentiator developed to enhance the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in individuals with cystic fibrosis. By increasing the gating activity of the CFTR channel at the cell surface, olacaftor helps improve chloride ion flow, reducing the thick mucus buildup characteristic of the disease. This pharmacological agent is particularly effective in patients with specific CFTR mutations, making it a crucial component in personalized medicine approaches for managing and treating cystic fibrosis.